Hershel Dobkin, MD, FAAD

home / authors / hershel-dobkin-md

Hershel Dobkin, MD, is a board-certified dermatologist based in Bexley, Ohio, specializing in both medical and surgical dermatology. Dobkin treats patients of all ages with special interest in skin cancer detection and treatment, nail surgery, acne, eczema, psoriasis, hair loss, autoimmune skin diseases and skin infections.

Articles

It's Not Genital Warts: A Clinician's Guide to Reassuring Men's Genital Concerns

It's Not Genital Warts: A Clinician's Guide to Reassuring Men's Genital Concerns

Hershel Dobkin, MD, FAAD
June 12th 2025

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic

Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic

Hershel Dobkin, MD, FAAD
May 14th 2025

Hershel Dobkin, MD, FAAD, discusses the surprising truth about toughness in dermatology, unexpected patient reactions, and the emotional depth behind appearances.

Practice What You Preach: A Clinician's Guide to Chemical Peels

Practice What You Preach: A Clinician's Guide to Chemical Peels

Hershel Dobkin, MD, FAAD
February 11th 2025

Dobkin underwent the procedure in order to connect with his patients considering it for themselves.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Published: November 17th 2023 | Updated: June 12th 2025
POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
Published: June 9th 2025 | Updated: June 12th 2025
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD
Published: June 7th 2025 | Updated: June 12th 2025
Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD
Evaluating Stress Levels in AD Treatment Plans
Published: November 9th 2023 | Updated: June 12th 2025
Evaluating Stress Levels in AD Treatment Plans
Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis
Published: June 7th 2025 | Updated: June 12th 2025
Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis
© 2025 MJH Life Sciences

All rights reserved.